Vulcan Value Partners LLC Trims Holdings in Medpace Holdings, Inc. $MEDP

Vulcan Value Partners LLC decreased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 76.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,306 shares of the company’s stock after selling 152,866 shares during the quarter. Medpace comprises 0.5% of Vulcan Value Partners LLC’s investment portfolio, making the stock its 28th largest holding. Vulcan Value Partners LLC’s holdings in Medpace were worth $26,580,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of MEDP. NewEdge Advisors LLC raised its position in Medpace by 22.1% in the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after purchasing an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Medpace by 3.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after purchasing an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. raised its position in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Sivia Capital Partners LLC purchased a new stake in Medpace in the 2nd quarter valued at $296,000. Finally, M&T Bank Corp raised its position in Medpace by 3.4% in the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after purchasing an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of Medpace stock opened at $428.00 on Thursday. The firm has a fifty day moving average of $457.76 and a two-hundred day moving average of $515.44. The company has a market cap of $12.22 billion, a P/E ratio of 26.90, a PEG ratio of 2.18 and a beta of 1.19. Medpace Holdings, Inc. has a one year low of $291.28 and a one year high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating the consensus estimate of $3.74 by $0.54. The firm had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business’s revenue for the quarter was up 26.5% compared to the same quarter last year. During the same quarter last year, the business earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities analysts predict that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Several firms, including Rosen, Glancy Prongay, Levi & Korsinsky, Schall, Pomerantz, and others, issued reminders about the ongoing class action and the June 8 lead-plaintiff deadline, keeping legal overhang front and center for shareholders. Article Title
• Negative Sentiment: One lawsuit notice specifically highlights allegations that Medpace misled investors about cancellation rates and book-to-bill ratio, and references a prior 16% stock drop tied to those disclosures, reinforcing fears of further liability or reputational damage. Article Title
• Neutral Sentiment: Zacks published a comparison of Medpace versus Labcorp on valuation, which may influence investor sentiment only modestly and does not appear to be a major stock-moving catalyst. Article Title

Insiders Place Their Bets

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 20.50% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the stock. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Leerink Partners cut their price objective on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research report on Wednesday, February 11th. BMO Capital Markets cut their price objective on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research report on Friday, April 24th. Robert W. Baird cut their price objective on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Finally, Royal Bank Of Canada cut their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $467.08.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.